Balanced news tone
News Sentiment
PRQR sentiment intelligence
ProQR Therapeutics BV news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
-4.4% over one week, +20.1% over four weeks, trend inactive, and near fair-value range.
ProQR Therapeutics (NASDAQ: PRQR) details 3.0M-share resale and balance sheet
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
ProQR Therapeutics (NASDAQ: PRQR) details 3.0M-share resale and balance sheet
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 21:13
- Source
- Stock Titan
Aescap group and Patrick Krol report ProQR (PRQR) shareholdings
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 15:55
- Source
- Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) CEO Boer Daniel Anton De Buys 150,000 Shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 13:23
- Source
- MarketBeat
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
[Form 4] ProQR Therapeutics N.V. Insider Trading Activity
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 12:00
- Source
- Stock Titan
Insider Buying: CEO de Boer Daniel Anton Acquires 150,000 Shares of ProQR Therapeutics NV
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 07:00
- Source
- GuruFocus
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Moderate Buy" by Brokerages
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 10 Jul 2026 06:21
- Source
- MarketBeat
ProQR (PRQR) CEO Daniel de Boer purchases 150,000 Ordinary Shares at $1.59
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 18:55
- Source
- Stock Titan
ProQR Registers Shares for Resale by Investor
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 21:38
- Source
- MT Newswires
ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis (NASDAQ:PRQR)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2026 07:00
- Source
- Seeking Alpha
Director Bart Filius buys 150,000 ProQR (PRQR) Ordinary Shares in open market
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- Stock Titan
ProQR (PRQR) director receives 14,595-share option grant at $1.42 strike
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- Stock Titan
Chardan Research Adjusts ProQR Therapeutics Price Target to $3 From $4, Maintains Buy Rating
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 26 Jun 2026 12:17
- Source
- MT Newswires
ProQR Therapeutics Says Phase 1 Trial of Liver Drug Candidate Meets Primary Endpoint
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 11:23
- Source
- MT Newswires
ProQR Therapeutics Prices $50 Million Underwritten Registered Direct Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 11:14
- Source
- MT Newswires
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 25 Jun 2026 10:25
- Source
- GlobeNewswire
ProQR Therapeutics (NASDAQ: PRQR) raises capital; Lilly to purchase 5.1M shares
- Tone
- Positive 66/100
- Event
- Balance sheet
- Published
- 25 Jun 2026 07:00
- Source
- Stock Titan
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- GlobeNewswire
ProQR’s first RNA editing drug shows human target engagement
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 25 Jun 2026 07:00
- Source
- Stock Titan
ProQR Therapeutics N.V. (PRQR) director awarded 14,495 stock options as compensation
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 07:00
- Source
- Stock Titan
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 12:25
- Source
- Simply Wall St.
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
ProQR Therapeutics: Waiting On Proof As AX-0810 Data Approaches (NASDAQ:PRQR)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Apr 2026 07:00
- Source
- Seeking Alpha
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView